Pfizer has launched messenger RNA (mRNA) collaborations with four companies, including an up-to-$1.35 billion partnership with base editing developer Beam Therapeutics, alliances with Codex DNA and Acuitas Therapeutics, and a third mRNA vaccine partnership with BioNTech.
Operator
Good afternoon, ladies and gentlemen, and welcome to the Dicerna Pharmaceuticals First Quarter 2021 Earnings Conference Call. As a reminder, this conference call is being recorded at the company s request.
I will now turn the call over to your host, Will Grammig of Stern IR. Please go ahead.
Lauren Stival
Investor Relations
Thank you, operator. Good afternoon, everyone, and thank you for joining us to review Dicerna s first quarter 2021 financial results and operational highlights. For anyone who hasn t yet had a chance to review our results we issued a press release after the close of trading today, which is available under the investors and media tab on our website at dicerna.com.